Cohen M, Chen Y, McCauley M, Gamble T, Hosseinipour M, Kumarasamy N, et al: Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011, 365: 493-505. 10.1056/NEJMoa1105243.
Grant R, Lama J, Anderson P, McMahan V, Liu A, Vargas L, et al: Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010, 363: 2587-2599. 10.1056/NEJMoa1011205.
Baeten J, Donnell D, Ndase P, et al: Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012, 367: 399-410. 10.1056/NEJMoa1108524.
Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, Henderson FL, Pathak SR, Soud FA, Chillag KL, et al: Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana. N Engl J Med. 2012, 367: 423-434. 10.1056/NEJMoa1110711.
Karim QA, Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, et al: Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women. Science. 2010, Epub:http://www.sciencemag.org/content/early/2010/07/19/science.1193748?explicitversion=true
Karim SSA: Results of the CAPRISA 004 trial of tenofovir gel. XVIII International AIDS Conference 18–23 July. 2010, Vienna, Austria
Cates W: After CAPRISA 004: time to re-evaluate the HIV lexicon. Lancet. 2010, 376: 495-496. 10.1016/S0140-6736(10)61200-7.
FACTS 001 Study. http://www.facts-consortium.co.za/?page_id=83,
Marrazzo J, Ramjee G, Nair G, Palanee T, Mkhize B, Nakabiito C, Taljaard M, Piper J, Gomez-Feliciano K, Chirenje M, VOICE Study Team: Pre-exposure Prophylaxis for HIV in Women: Daily Oral Tenofovir, Oral Tenofovir/Emtricitabine, or Vaginal Tenofovir Gel in the VOICE Study (MTN 003). 20th Conference on Retroviruses and Opportunistic Infections; March 3–6. 2013, Atlanta, Georgia, USA
Bärnighausen T, Bloom DE, Humair S: Economics of antiretroviral treatment vs. circumcision for HIV prevention. Proc Natl Acad Sci U S A. 2012, 109: 21271-21276. 10.1073/pnas.1209017110.
Shisana O, Rehle T, Simbayi L, Zuma K, Jooste S, Pillay-van-Wyk V, Mbelle N, Van Zyl J, Parker W, Zungu N, et al: South African national HIV prevalence, incidence, behaviour and communication survey. A turning tide among teenagers?. 2009, Cape Town: HSRC Press
Shisana O, Rehle T, Simbayi L, Parker W, Zuma K, Bhana A, Connolly C, Jooste S, Pillay V: South African National HIV Prevalence. 2005, Behaviour and Communication Survey: HIV Incidence
Dunkle K, Beksinka M, Rees H, Ballard R, Htun Y, Wilson ML: Risk factors for HIV infection among sex workers in Johannesburg, South Africa. Int J STD AIDS. 2005, 16: 256-261. 10.1258/0956462053420220.
RHRU: Reproductive Health Research Unit Behavioural Sentinel Survey Data Report - Clients of family planning - Gauteng. 2000, Johannesburg, South Africa: Reproductive Health Research Unit, University of the Witwatersrand
Watts C, Foss A, Kumaranayake L, Cox A, Terris-Prestholt F, Vickerman P: Identifying optimal strategies for microbicide distribution in India and South Africa: Modelling and cost-effectiveness analyses. International Partnership for Microbicides with the London School of Hygiene and Tropical Medicine. 2008, Brussels and London
Rees H: Service Delivery and Demand Challenges in Introducing new health products. 2008, Mexico City: Microbicide Access Forum
Department of Health Medical Research Council, OrcMacro: South Africa Demographic and Health Survey 2003. 2007, Pretoria: Department of Health Republic of South Africa
Heise L, Watts C, Foss A, Vickerman P, Trussell J, Hayes R, McCormack S: Apples and oranges? Interpreting success in HIV prevention trials. Contraception. 2011, 83: 10-15. 10.1016/j.contraception.2010.06.009.
Vickerman P, Foss A, Watts C: Using modeling to explore the degree to which a microbicide's sexually transmitted infection efficacy may contribute to the HIV effectiveness measured in phase 3 microbicide trials. J Acquir Immune Defic Syndr. 2008, 48: 460-467. 10.1097/QAI.0b013e31817aebd6.
Vickerman P, Watts C, Delany S, Alary M, Rees H, Heise L: The importance of context: model projections on how microbicide impact could be affected by the underlying epidemiologic and behavioral situation in 2 African settings. Sex Transm Dis. 2006, 33: 397-405. 10.1097/01.olq.0000218974.77208.cc.
Vickerman P, Foss AM, Pickles M, Deering K, Verma S, Demers E, Moses S, Alary M, Boily M-C: Is the Indian HIV epidemic driven by commercial sex? A modelling analysis from south India. AIDS. 2010, 24: 2563-2572. 10.1097/QAD.0b013e32833e8663.
Garnett GP, Anderson RM: Strategies for limiting the spread of HIV in developing countries: conclusions based on studies of the transmission dynamics of the virus. J Acquir Immune Defic Syndr Hum Retrovirol. 1995, 9: 500-513.
Weinstein MC, Graham JD, Siegel JE, Fineberg HV: Cost-effectiveness analysis of AIDS prevention programs: concepts, complications and illustrations. Confronting AIDS. Edited by: Turner CF, Miller HG, Moses LE. 1989, Washington DC: National Academy Press, 471-499.
Foss AM, Vickerman PT, Mayaud P, Weiss H, Ramesh BM, Reza-Paul S, Washington R, Blanchard J, Moses S, Lowndes CM, et al: Modelling the interactions between HSV-2 and HIV: implications for the HIV epidemic in southern India. Sex Transm Infect. 2011, 87: 22-27. 10.1136/sti.2009.041699.
Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, Laeyendecker O, Kiwanuka N, Kigozi G, Kiddugavu M, Lutalo T, et al: Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis. 2005, 191: 1403-1409. 10.1086/429411.
Shisana O, Simbayi L: Nelson Mandela/HSRC study of HIV/AIDS. South African National HIV Prevalence, Behavioural Risks and Mass Media. 2002, The Human Sciences Research Council: Cape Town
Johnson LF, Coetzee DJ, Dorrington RE: Sentinel surveillance of sexually transmitted infections in South Africa: a review. Sex Transm Infect. 2005, 81: 287-293. 10.1136/sti.2004.013904.
CHOosing Interventions that are Cost Effective (WHO-CHOICE). [http://www.who.int/choice/costs/CER_thresholds/en/]
Bassett IV, Giddy J, Nkera J, Wang B, Losina E, Lu Z, Freedberg KA, Walensky RP: Routine voluntary HIV testing in Durban, South Africa: the experience from an outpatient department. J Acquir Immune Defic Syndr. 2007, 46: 181-186. 10.1097/QAI.0b013e31814277c8.
Terris-Prestholt F, Kumaranayake L, Obasi AI, Cleophas-Mazige B, Makokha M, Todd J, Ross DA, Hayes RJ: From Trial Intervention to Scale-Up: Costs of An Adolescent Sexual Health Program in Mwanza, Tanzania. Sex Transm Dis. 2006, 33: S133-139. 10.1097/01.olq.0000200606.98181.42.
Terris-Prestholt F, Michaels C, Kumaranayake L, Meyer-Rath G, Watts C: Costing Microbicide Distribution: Estimating cost-effectiveness & modelling potential role out. 2009, Entebbe, Uganda: MDP301 Annual Investigators Meeting
Meyer-Rath G: Public Sector Salary Costs. 2009, Personal Communicatuion
Cleary S, Bouille A, McIntyre D, et al: Cost-effectiveness of Antiretroviral Treatment for HIV-positive Adults in a South African Township. 2004, Cape Town: University of Cape Town, Health Systems Trust, Medecins Sans Frontieres
Gilson L, Mkanje R, Grosskurth H, Mosha F, Picard J, Gavyole A, Todd J, Mayaud P, Swai R, Fransen L, et al: Cost-effectiveness of improved treatment services for sexually transmitted diseases in preventing HIV-1 infection in Mwanza Region, Tanzania. Lancet. 1997, 350: 1805-1809. 10.1016/S0140-6736(97)08222-6.
Bollinger L, Stover J, Boulle A, Cleary S: Database of Unit Costs for HIV and AIDS interventions in South Africa: Resource Needs for HIV/AIDS: Model for estimating resources needed for prevention, care and mitigation. Book Database of Unit Costs for HIV and AIDS interventions in South Africa: Resource Needs for HIV/AIDS: Model for estimating resources needed for prevention, care and mitigation. 2006, City: Centre for Economic Governance and AIDS in Africa
Friend D: Tenofovir 1% gel, Current Prices and Expected Prices at Different Scales. 2012, Personal communication
Johnson L: Access to antiretroviral treatment in South Africa, 2004–2011. S Afr J HIV Med. 2012, march: 22-27.
Meyer-Rath G: National ART Cost Model, South Africa. 2011, Johannesburg: Health Economics and Epidemiology Research Office, Boston University/University of the Witwatersrand
Johansson KA, Robberstad B, Norheim OF: Further Benefits by Early Start of HIV Treatment in Low Income Countries: Survival Estimates of Early Versus Deferred Antiretroviral Therapy. AIDS Res Ther. 2010, 7: 3-10.1186/1742-6405-7-3. doi:10.1186/1742-6405-7-3
Fox-Rushby JA, Hanson K: Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysis. Health Policy Plan. 2001, 16: 326-331. 10.1093/heapol/16.3.326.
Ortblad KF, Lozano R, Murray CJ: The burden of HIV: insights from the GBD 2010. AIDS (London, England). 2013
GDP per capits (current US$). http://data.worldbank.org/indicator/NY.GDP.PCAP.CD,
Kashuba AD, Abdool Karim SS, Kraft E, White N, Sibeko S, Werner L, Mansoor LE, Gengiah T, Sidhoo S, Abdool Karim Q: Do systemic and genital tract tenofovir concentrations predict HIV seroconversion in the CAPRISA 004 tenofovir gel trial?. XVIII International AIDS Conference 18–23 July. 2010, Vienna, Austria
Watts CH, Kumaranayake L, Vickerman P, Terris-Prestholt F: The public health impact of microbicides: model projections. Report from the Public Health Benefits Working Group. The Rockefeller Foundation Microbicide Initiative. 2002, http://www.global-campaign.org/clientfiles/rep7_publichealth.pdf,
Watts C, Vickerman P: The impact of microbicides on HIV and STD transmission: model projections. AIDS. 2000, 15: S43-S44.
Vickerman P, Devine A, Foss AM, Delany-Moretlwe S, Mayaud P, Meyer-Rath G: The cost-effectiveness of herpes simplex virus-2 suppressive therapy with daily aciclovir for delaying HIV disease progression among HIV-1-infected women in South Africa. Sex Transm Dis. 2011, 38: 401-409. 10.1097/OLQ.0b013e31820b8bc8.
Terris-Prestholt F, Kumaranayake L, MacPhail C, Rees H, Watts C: Determinants of South African Women’s Demand for New Barrier Methods and their Distribution: Analysis of a Discrete Choice Experiment. IAEN; 1–2 August; Cuernavaca. 2008
Foss AM, Vickerman PT, Heise L, Watts CH: Shifts in condom use following microbicide introduction: should we be concerned?. AIDS. 2003, 17: 1227-1237. 10.1097/00002030-200305230-00015.
Williams BG, Karim SSA, Karim QA, Gouws E: Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa. J Acquir Immune Defic Syndr. 2011, 58: 207-210. 10.1097/QAI.0b013e3182253c19.
Walensky RP, Park JE, Wood R, Freedberg KA, Scott CA, Bekker LG, Losina E, Mayer KH, Seage GR, Paltiel AD: The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women. Clin Infect Dis. 2012, 54: 1504-1513. 10.1093/cid/cis225.
Verguet S, Walsh JA: Vaginal microbicides save money: a model of cost-effectiveness in South Africa and the USA. Sex Transm Infect. 2010, 86: 212-216. 10.1136/sti.2009.037176.
MDP Statement on the Discontinuation of Tenofovir gel in the VOICE Trial. http://www.mdp.mrc.ac.uk/,
Gray RH, Li X, Kigozi G, Serwadda D, Nalugoda F, Watya S, Reynolds SJ, Wawer M: The impact of male circumcision on HIV incidence and cost per infection prevented: a stochastic simulation model from Rakai, Uganda. AIDS. 2007, 21: 845-850. 10.1097/QAD.0b013e3280187544.
Hallett TB, Singh K, Smith JA, White RG, Abu-Raddad LJ, Garnett GP: Understanding the impact of male circumcision interventions on the spread of HIV in southern Africa. PLoS One. 2008, 3: e2212-10.1371/journal.pone.0002212.
White RG, Glynn JR, Orroth KK, Freeman EE, Bakker R, Weiss HA, Kumaranayake L, Habbema JD, Buve A, Hayes RJ: Male circumcision for HIV prevention in sub-Saharan Africa: who, what and when?. AIDS. 2008, 22: 1841-1850. 10.1097/QAD.0b013e32830e0137.
Cox AP, Foss AM, Vickerman PT, Chimbwete C, Okonji E, Terris-Prestholt F, Beksinska M, Walaza S, von Mollendorf C, Smit J, et al: Making realistic impact projections for new HIV prevention technologies: looking beyond a product’s efficacy. 18th International Society for Sexually Transmitted Diseases Research; 28 June - 1 July. 2009, London, UK
Central Bank Rates. http://www.cbrates.com,